Skip to main content
Fig. 7 | Journal for ImmunoTherapy of Cancer

Fig. 7

From: Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism

Fig. 7

Tritherapy efficacy is independent of antigen presentation by peritumorally administered APCs. a, Line-1-tumor bearing mice were treated i.p. with anti-GITR antibody on days 5 and 8 and anti-PD-1 antibody on days 10, 12, and 14. Line-1 cell derived DRibbles were peritumorally administered on day 12. Individual tumor growths and overall survival is shown. Representative data from 1 experiment is shown (n = 5). b, Panc02-tumor bearing mice were treated as in a except DRibbles were derived from the Panc02 cell line. Representative data from 1 experiment is shown (n = 5). c, Washed unpulsed and DRibbles-pulsed day 8 BMCs were cultured for 24 h after which the supernatant was collected and analyzed by ELISA for IL-1beta, IL-6 or IL-12p40. Type I IFN presence in the supernatant was analyzed using B16Blue-IFNa/b cells. Data (mean ± SD) from one independent experiment performed in triplicate wells for IL-1β and IL-6 or duplicate wells for IL-12p40 and Type I IFNs is shown. d, Line-1 tumor bearing BALB/c mice were treated with BMC-tritherapy using BMCs derived from either syngeneic BALB/c mice or allogeneic C57BL/6 mice bone marrows. BMCs were pulsed with Line-1 cell-derived DRibbles before peritumoral administration. Representative data from 1 experiment is shown (n = 5). e, Same as d however mice were treated with syngeneic BALB/c or allogeneic C57BL/6 CD103+ DCs pulsed with DRibbles derived from Line-1 cells. Representative data from 1 experiment is shown (n = 5)

Back to article page